Abstract:Lung cancer represents the leading cause of cancer-related deaths worldwide due to its high incidence and the lack of effective therapies. Current pharmacological strategies for the treatment of advanced stage disease are in fact largely ineffective mostly due to the emergence of drug resistance. The cancer stem cell (CSC) hypothesis suggests that treatment failure and tumor relapse may be explained by the existence of a subset of self-renewing cancer cells endowed with tumor-initiating potential which are able to escape conventional and targeted therapies and to regenerate tumors.In this chapter we will first focus on the description of studies which led to identification and characterization of CSCs in lung cancer according to their expression of specific markers and/or functional properties and will discuss the potential clinical value of CSC-related markers to predict patients’ outcome and response to therapies. We will next review evidences supporting the proposed mechanisms of resistance of CSCs to chemotherapy and targeted therapies and in particular intrinsic CSCs’ properties such as enhanced activation of the DNA damage repair machinery and anti-apoptotic signaling, increased expression of drug transporters, activation of self-renewal pathways, and quiescence status. The ability of tumor microenvironment (TME)-derived signals to modulate CSC phenotype, especially through the induction of epithelial mesenchymal transition, has also been demonstrated to contribute to drug resistance. Here we will discuss the interconnection among TME signals, modulation/generation of CSC, and development of resistance to both conventional and targeted therapy in lung cancer. Finally we will present novel strategies based on targeting of specific pathways activated in CSCs or able to impair the cross talk between TME and CSCs and aimed at eradication of the CSC subsets, which have been already tested or are currently under investigation in clinical trials in advanced lung cancer.Despite some still ongoing controversies regarding the best strategy/markers to define the stem cell population in lung cancer, several evidences support the resistance of lung CSC to conventional and targeted therapies providing a new perspective for the understanding of drug resistance mechanisms and indicating the path for development of innovative targeted therapies that may ultimately improve clinical outcome of lung cancer patients.

Current perspectives on the crosstalk between lung cancer stem cells and cancer-associated fibroblasts

Cancer‐associated Fibroblasts in Breast Cancer: Challenges and Opportunities

Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives

Cancer Stem Cells in Lung Cancer: Roots of Drug Resistance and Targets for Novel Therapeutic Strategies

Research Status and Controversy on Non-Small Cell Lung Cancer Stem Cells.

Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments

Lung cancer stem cells: tools and targets to fight lung cancer

Crosstalk between CAFs and tumour cells in head and neck cancer

Crosstalk and communication of cancer-associated fibroblasts with natural killer and dendritic cells: New frontiers and unveiled opportunities for cancer immunotherapy

Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets

Cancer-associated fibroblasts and prostate cancer stem cells: crosstalk mechanisms and implications for disease progression

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

Cancer Stem Cells from Definition to Detection and Targeted Drugs

Can Lung Cancer Stem Cells Be Targeted for Therapies?

Crosstalk between cancer‐associated fibroblasts and immune cells in cancer

Cancer stem cells: advances in knowledge and implications for cancer therapy

Cancer stem cell–immune cell crosstalk in tumour progression

Therapeutic Targeting of Cancer-Associated Fibroblasts in the Non-Small Cell Lung Cancer Tumor Microenvironment

Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies

Extracellular vesicles in non-small cell lung cancer stemness and clinical applications

Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers